KalVista Pharmaceuticals (KALV) Leerink Global Healthcare Conference 2025 summary

Regulatory and clinical progress

• Sebetralstat is under review for on-demand treatment of hereditary angioedema (HAE) in seven territories, with a key U.S. PDUFA date set for June 17 and EU launch expected later this year.

• The regulatory review is proceeding smoothly, with mid-cycle and late-cycle meetings scheduled, and no advisory committee required by the FDA.

• Clinical data show robust efficacy and safety, with all primary and secondary endpoints met and no serious adverse events across over 1,700 attacks.

• Efficacy is consistent across all HAE subgroups, including severe and laryngeal attacks, and in patients on prophylaxis.

• Additional regulatory filings are underway in the UK, Japan, and other territories, supporting a global commercial rollout.

Commercial launch strategy

• A 32-person field team was onboarded in February, already engaging with over half of the top 1,000 HAE-prescribing physicians.

• The sales force is experienced in HAE and allergy, targeting a concentrated prescriber base, with plans for multiple pre-approval meetings to build relationships.

• Launch preparations include a Quick Start program to facilitate early patient access, with initial uptake expected to follow standard launch curves but with some early variability.

• The product will be sold in a multi-pack, with a portable, blistered tablet format designed for convenience and increased treatment rates.

• Commercial updates and launch metrics will be shared at an upcoming commercial day to provide transparency on launch dynamics.

Market opportunity and competitive landscape

• The on-demand HAE market remains underserved, as prophylaxis therapies, despite high efficacy, do not eliminate attacks for most patients.

• Data show that only about two-thirds of attacks are currently treated, largely due to burdensome administration of existing therapies; sebetralstat’s ease of use could increase this rate to 80% or higher.

• The product is positioned as a premium therapy, with expected pricing in the $11,000–$16,000 per dose range, supported by strong payer interest and favorable pharmacoeconomics compared to both on-demand and prophylaxis options.

• The launch is expected to benefit from both motivated physicians, due to strong clinical data, and activated patients, as seen in prior oral therapy launches.

• The global strategy aims to address unmet needs in HAE treatment worldwide, with rapid expansion planned beyond the U.S. and EU.